StockData

Nu-Med Plus, Inc. (NUMD) shareholders

NUMDOTCGold and Silver OresFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.01−0.00 (-8.16%)

Close on Oct 19, 2026Market cap $601.55KP/E –Yield –

Ownership

Who owns Nu-Med Plus's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Fred Tejada8,131,2509.70%13D (active)Jul 8, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Fred TejadaSVP and Chief Geologist, Director, 10% owner16,381,25019.61%Aug 25, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Fred Tejada
SVP and Chief Geologist, Director, 10% owner
Jul 8, 2026Award+1,000,000––1,000,000
Fred Tejada
SVP and Chief Geologist, Director, 10% owner
Jul 8, 2026Other+16,381,250––16,381,250
William C. Hayde
Chief Executive Officer, Director
Nov 7, 2023Award+1,000,000$0.02$20.00K1,000,000
Jeffrey Lynn Robins
Director
Nov 7, 2023Award+200,000$0.02$4.00K5,200,000
Craig Morrison
Vice President of Technology, Director
Aug 5, 2016Other−2,000,000––2,000,000
Brett J. Earl
VP of Medical Marketing, Director
Apr 23, 2015Award+800,000––1,000,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
0.0%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nu-Med Plus's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?